New synthesis technologyUsing a new modification of standard Fmoc chemistry for peptide synthesis, Eurogentec now offers the synthesis of custom peptide libraries in 96-well format for high-throughput screening purposes. Peptide libraries include- 200 – 500 µg of each peptide
- 96-well format
- Unbound, free crude peptides
- Lengths between 5-18 amino acids
- Amino N-terminus
- CONH2 C-terminus
- MALDI-TOF QC on 10 % of peptides
Requirements - Excel format list of peptides to synthesize
| Name |
Length (AA) |
Quantity |
Reference |
EUR |
|
| Basic peptide library |
5 |
< 1 mg |
AS-HTPP-CR05 |
45.00 |
|
| Basic peptide library |
6 |
< 1 mg |
AS-HTPP-CR06 |
45.00 |
|
| Basic peptide library |
7 |
< 1 mg |
AS-HTPP-CR07 |
45.00 |
|
| Basic peptide library |
8 |
< 1 mg |
AS-HTPP-CR08 |
45.00 |
|
| Basic peptide library |
9 |
< 1 mg |
AS-HTPP-CR09 |
45.00 |
|
| Basic peptide library |
10 |
< 1 mg |
AS-HTPP-CR10 |
45.00 |
|
| Basic peptide library |
11 |
< 1 mg |
AS-HTPP-CR11 |
45.00 |
|
| Basic peptide library |
12 |
< 1 mg |
AS-HTPP-CR12 |
45.00 |
|
| Basic peptide library |
13 |
< 1 mg |
AS-HTPP-CR13 |
45.00 |
|
| Basic peptide library |
14 |
< 1 mg |
AS-HTPP-CR14 |
45.00 |
|
| Basic peptide library |
15 |
< 1 mg |
AS-HTPP-CR15 |
45.00 |
|
| Basic peptide library |
16 |
< 1 mg |
AS-HTPP-CR16 |
45.00 |
|
| Basic peptide library |
17 |
< 1 mg |
AS-HTPP-CR17 |
45.00 |
|
| Basic peptide library |
18 |
< 1 mg |
AS-HTPP-CR18 |
45.00 |
|
Peptides are supplied unbound, SePop purified. Average purity >60% Quality Control
Mass Spectrometry Delivery times
10-15 days Packaging
individual tubes Shipping conditions
RT Storage conditions
-20°C, anhydrous conditions
New peptide synthesis technologyUsing a new modification of standard Fmoc chemistry for peptide synthesis, Eurogentec now offers the synthesis of custom peptide libraries in 96-well format for high-throughput screening purposes. Peptide libraries include - 200 – 500 µg of each peptide
- 96-well format
- Unbound, free crude peptides
- Lengths between 5-18 amino acids
- Amino N-terminus, CONH2 C-terminus
- MALDI-TOF QC on 10 % of peptides
Requirements: An Excel® formated list of peptides to synthesise. Applications- Epitope mapping
- Alanine walking
- Single amino acid mutation screening
- Protein-protein interaction studies
- Kinase motif discovery
- Protease motif discovery
Epitope MappingEpitopes recognized by antibodies are commonly 6 amino acids in length. By generating overlapping 15 mer peptides, each shifted by 4 amino acids, one can unequivocally determine which amino acids make up the epitope. Schematically the approach looks as follows based on the following simplified “protein” example: ..KNCSHIQPWETDCLSCLPERQDEYDPKGPKVSDG 1.KNCSHIQPWETDCLS 2....SHIQPWETDCLSCLP 3.......QPWETDCLSCLPERQ 4..........ETDCLSCLPERQDEY 5.............CLSCLPERQDEYDPK 6................CLPERQDEYDPKGPK 7...................ERQDEYDPKGPKVSD 8......................DEYDPKGPKVSDG 9.........................DPKGPKVSDG 10...........................GPKVSDG
T-Cell StimulationLibraries can also be generated to see which particular peptide from an antigenic protein is responsible for a T-cell response. The design process is similar to the epitope mapping example above. Mutation Studies using Alaine WalkingBy screening peptides with systematic replacement of each amino acid with alanine, one can determine to which extent a particular amino acid is required and sufficient for an interaction. Purification Selective precipitation (SePop) QC 10% QC by MALDI Legal notices For research use only
LeafletsFAQ | What type of chemistry do you use? |
|---|
 | Eurogentec uses solid phase Fmoc chemistry rather than tBOC chemistry. Peptides synthesised by tBOC chemistry require more purification due to the harsh synthesis conditions and specific equipment related to the use of hydrofluoric acid (HF). |
|---|
 | What quality control (QC) information do you provide? |
|---|
 | All peptides are analysed by MS to confirm the molecular weight. For peptides where a minimum purity has been requested we also run reverse-phase HPLC analyses. The results from these analyses are included on the Technical Datasheet (TDS) supplied with the peptides delivered. |
|---|
-
 | How should my peptide be stored? |
|---|
 | Lyophilized peptides should be stored away from heat, light and moisture. Under these conditions lyophilised peptides are stable at room temperature for days to weeks, for longer term storage, peptides should be stored under the same conditions but at -20 °C.
As moisture will greatly reduce the long term stability of peptides, peptides should be allowed to equilibrate to room temperature in a desiccator before dispensing, thus avoiding exposure to moisture in the air which will condense on the peptide. Once dispensed, the tube should be gently purged with anhydrous nitrogen or argon, the container recapped, sealed with parafilm and stored at -20 °C.
In solution, some slow degradation reactions could take place, the rate of which will be sequence dependent. Possible degradation reactions in solution include:
- Oxidation of Cys, Met and Trp
- Deamidation of Gln and Asn to Glu and Asp respectively
- Oxidative cyclisation to form Cys-Cys
|
|---|
 | How do I know if my peptide will be soluble? |
|---|
 | The solubility of a peptide is often hard to predict and in the more difficult cases requires multiple attempts to find the best combination of solvents and pH. Please see "How should I solubilise my peptide". |
|---|
 | How should I solubilize my peptide? |
|---|
 | Peptide solubility characteristics vary strongly from one peptide to another and are very difficult to predict. Residues such as Ala, Cys, Ile, Leu, Met, Phe, and Val will increase the chance of the peptide having solubility problems.
The best solvent to use will depend on the solubility properties of the peptide and solvent requirements of your assay. We recommend predicting the physical properties of the peptide, dissolving the peptide as a function of these physical properties and then adapting the solubility results experimentally.
1. From the technical datasheet note the "Charge at pH 7" parameter
2. Calculate the percentage of hydrophobic residues
A. If the "Charge at pH 7" is negative and percent hydrophobic residues is < 50 %
1. Dissolve the peptide in a minimum amount of sterile distilled water and sonicate if necessary, if it goes in solution dilute to the desired peptide concentration with assay solution
2. If not add in a dropwise fashion (50 uL) of 0.1N acetic acid in sterile distilled water to the desired peptide concentration for your assay and sonicate if necessary. Acetic acid is volatile and will be removed during lyophilization should the peptide not go into solution.
3. If the peptide still does not go into solution then lyophilise and go to procedure C
B. If the "Charge at pH 7" is positive and percent hydrophobic residues is < 50 %
1. Dissolve the peptide in a minimum amount of sterile distilled water and sonicate if necessary, if it goes in solution dilute to the desired peptide concentration with assay solution.
2. If not add in a dropwise fashion (50 uL) of 0.1N ammonium bicarbonate in sterile distilled water to the desired peptide concentration for your assay and sonicate if necessary. Ammonium bicarbonate is volatile and will be removed during lyophilization should the peptide not go into solution.
3. If the peptide still does not go into solution then lyophilise and go to procedure C
C. If the percent hydrophobic residues > 50 %
1. Dissolve the peptide in a minimum amount of acetonitrile or isopropanol. These solvents are useful for solubilising organic compounds, and can still be removed by lyophilization. If the material does not go into solution then sonicate. Once in solution dilute to the desired peptide concentration with assay solution.
2. If not dissolve the peptide in a minimum amount of DMSO or DMF. These solvents are useful for solubilising organic compounds, but due to their very high boiling points are difficult to remove by lyophilization. If the material does not go into solution then sonicate. If the peptide goes into solution dilute to the desired peptide concentration with assay solution.
3. If not then the use of chaotropic salts such as guanidine hydrochloride or urea is recommended. These will dissolve most peptides, the choice of which will depend on the compatibility with your assay system. |
|---|
-
 | How do you confirm a peptide is cyclised? |
|---|
 | There are two types of cyclisations that can be performed:
1. N-terminal to C-terminal cyclisation
2. Disulfide bridge cyclisation
N-terminal to C-termal cyclisation is confirmed by a molecular weight shift of 18 mass units in the Maldi-Tof mass spectrum. A disulfide bridge cyclisation is confirmed by MS and HPLC before and after the cyclisation step. Although a mass shift of 2 mass units can be difficult to detect for certain peptides, an HPLC shift helps confirm the completion of the reaction. |
|---|
 | Do you synthesize 'wobble' peptides? |
|---|
 | Yes, we can synthesize wobble peptides. As there are known differences in the incorporation rates of different amino acids, we can compensate for these rates to produce roughly equimolar amounts of each wobble peptide. |
|---|
-
 | What is gross peptide weight? |
|---|
 | The gross peptide weight is the weight determined after weighing the peptide. This is the amount indicated on the tube. |
|---|
 | What does net peptide content mean? |
|---|
 | The gross weight of dry peptide doesn't consist of peptide only, but includes non-peptide components such as water, absorbed solvents, counter ions and salts. Net peptide content is the actual percent weight of peptide from the gross weight. This number may vary, from 50-90 percent, depending on the purity, sequence and method of synthesis and purification. |
|---|
 | What is the difference between peptide content and peptide purity? |
|---|
 | Peptide content is not an indication of peptide purity; these are two measurements. Purity is determined by HPLC and indicates the presence/absence of contaminating peptides with undesired sequences. Net peptide content only gives information on the percent of total peptide versus total non-peptide components independently of the presence of multiple peptides. Net peptide content is accurately found by performing amino acid analysis or UV spectrophotometry. This information is important when calculating concentrations of peptide during sensitive experiments. |
|---|
 | How do you generally purify your peptides? |
|---|
 | Our peptides are generally purified by preparative reversed phase HPLC, using two tri-fluoro acetic acid (TFA) modified buffers at pH 2. Buffer A is 0.1 % TFA in deionised water and buffer B is 0.1 % TFA in acetonitrile (ACN) at pH 2. Peptides are dissolved in either straight buffer A, or some amount of buffer B then diluted with buffer A. Sometimes it is necessary to use an organic polar solvent like (formic acid or acetic acid) in DMSO or DMF to aid in the dissolving of hydrophobic peptides but this is done on a case-by-case basis depending on the sequence anaylsis. On rare occasions we can get better solubility and therefore better purification at pH 6.8 so in that case we dissolve the peptide and run the gradient using two alternate buffers. The pH 6.8 buffers we use are 10 mM ammonium acetate in deionised water (buffer A) or ACN (buffer B). The separation is monitored by UV at 214 nm and fractions are collected and analysed by MADLI-TOF mass spectrometry for product identity and by reversed phase analytical HPLC for purity. The fractions are then lyophilised to remove the solvents. The fractions that meet the specifications of the order are then combined into one vial. Next, we run a final MALDI-TOF and analytical HPLC on the combined material. |
|---|
 | What is MALDI-TOF? |
|---|
 | MALDI stands for Matrix Assisted Laser Desorption - Time of Flight. This machine is used to determine the mass of molecules present in a sample. We can confirm that we have the correct peptide by comparing the theoretical molecular mass of the peptide synthesized with the experimentally determine molecular mass of the synthetic material. |
|---|
 | Can you explain the M+Na and M+K mass peaks in MALDI spectra? |
|---|
 | It is very common to see Na (sodium) and K (potassium) adducts in the MALDI spectrum. The sodium and potassium comes from the water used in the peptide solvents. Even distilled and deionized water has trace amounts of sodium and potassium ions, which can never be entirely removed. These become ionized during the MALDI mass spec process and bind to the free carboxyl groups of the peptide. Because there is no water purification system that will remove every single sodium or potassium ion from water, seeing the sodium and potassium adducts at times is very common and unavoidable in MALDI mass spec. This is not an indication that the peptide is not pure, nor should it be confused with an incorrect molecular weight. |
|---|
 | How long should a peptide that is going to be used as an antigen for antibody production be? |
|---|
 | We usually use peptides that are 13 to 15 amino acids long in length, however shorter and longer peptides have been known to work. We have successfully raised anti-peptide antibodies to peptides that differ in the presence/absence of a single phosphate (our phospho-specific antibody programme). Antibodies typically recognise epitopes are typically between 6-8 amino acids, by presenting a peptide that is 15 amino acids long we increase the likelihood of generating useful antibodies but limit the chance of producing a peptide with a secondary structure that might be unrelated to the antigen. |
|---|
 | What should I do with the ends of my peptides, keep them free or block them? |
|---|
 | In order to mimic a protein's physical and chemical properties, you should request peptides that have a similar structure and charge to the protein. For peptide sequences that represent the N-terminus we recommend keeping the N-terminus as NH2 like in the protein, and modifying the C-terminus with an amide group to mimic a peptide linkage. For peptide sequences that represent the C-terminus we recommend keeping the C-terminus as COOH like in the protein and modifying the N-terminus with an acetyl group to mimic a peptide linkage. For internal peptides both ends of the peptide should be modified (N-terminal acetyl and C-terminal amide) to mimic both peptide linkages. |
|---|
 | What methods do you recommend to conjugate a peptide to a carrier molecule? |
|---|
 | The most important factor is that the site of conjugation be not an internal amino acid and that the site of conjugation be specific for a single amino acid. Internal amino acids and multiple conjugation sites will not present the peptide in a way that is most similar to the natural antigen. After that the choice of chemistry will be dependent on the type of amino acids present in the sequence.
|
Chemistry
|
Site of reaction
|
Not in the presence of
|
Comments
|
|
Glutaraldehyde
|
N-terminal NH2 group
|
Lys (K) or an acetylated N-terminus or a Pro(P) N-terminus
|
Not useful for peptides that correspond to the N-terminus of the antigen
|
|
EDCI
|
C-terminal COOH group
|
Glu (E), Asp (D) or an amidated C-terminus
|
Not useful for peptides that correspond to the C-terminus of the antigen
|
|
MAP-8
|
C-terminal COOH group
|
-
|
Lower antigenicity than coupling to a carrier protein
|
|
BDB
|
Terminal tyrosine
|
Another Tyr (Y), Lys (K), Cys (C), His (H)
|
Limited utility
|
|
MBS
|
Side chain thiol of cysteine
|
Another Cysteine (C)
|
Commonly used approach, usually via the addition of an extra Cys (C) to the sequence at either the N- or C-terminus
|
|
|---|
Product citationsBECAMEL C. et al., "The Serotonin 5-HT2A and 5-HT2C Receptors Interact with Specific Sets of PDZ Proteins", Journal of Biological Chemistry, vol. 279, n° 19, p. 20257-20266, May 2004 BOUDSOCQ M. et al., "Identification of Nine Sucrose Nonfermenting 1-related Protein Kinases 2 Activated by Hyperosmotic and Saline Stresses in Arabidopsis thaliana", Journal of Biological Chemistry, vol. 279, n° 40, p. 41758-41766, October 2004 MORGAN C. et al., "Phosphorylation of a Distinct Structural Form of Phosphatidylinositol Transfer Protein a at Ser166 by Protein Kinase C Disrupts Receptor-mediated Phospholipase C Signaling by Inhibiting Delivery of Phosphatidylinositol to Membranes", Journal of Biological Chemistry, vol. 279, n° 45, p. 47159-47171, November 2004 BIKKER F. et al., "Bacteria Binding by DMBT1/SAG/gp-340 Is Confined to the VEVLXXXXW Motif in Its Scavenger Receptor Cysteine-rich Domains", Journal of Biological Chemistry, vol. 279, n° 46, p. 47699-47703, November 2004 SIX E. et al., "The Notch Ligand Delta1 Recruits Dlg1 at Cell-Cell Contacts and Regulates Cell Migration", Journal of Biological Chemistry, vol. 279, n° 53, p. 55818-55826, December 2004 MIGEOTTE et al., "Identification and characterization of an endogenous chemotactic ligand specific for FPRL2", JEM, vol. 201, n° 1, 1-12, January 2005
Please provide all of the following information so that we may begin to process your order
| |
• Peptide sequence, quantity, purity and the following
• Purchase order number from your institute
• Product references and prices
• Other important production information
|
|
| |
Delivery information
• Name
• Shipping Address
• Telephone
• Email |
Invoicing information
• Name
• Shipping Address
• Telephone
• Email
|
|
- Online
You can place your order online. Login to access our web ordering interface.
- By mail
Eurogentec S.A.
LIEGE Science Park
Rue du Bois Saint Jean 5
4102 Seraing
BELGIUM
If you still have questions with ordering please contact our Customer Support : +32 4 372 76 65.
|